Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis.
D000208:Acute Disease; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000917:Antibody Formation; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D004185:Disability Evaluation; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006453:Hemoglobinopathies / Q000139:chemically induced; D006801:Humans; D007165:Immunosuppression Therapy; D007239:Infections / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000628:therapy*; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced; D013950:Thymus Gland / Q000276:immunology*; D014581:Urticaria / Q000139:chemically induced
D000961:Antilymphocyte Serum; D000324:Adrenocorticotropic Hormone